17,261 trials
PDAC - Pancreatic Ductal Adenocarcinoma · FAP
Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants
Gynecologic Cancer · Gynecologic Neoplasms · Peritoneal Carcinomatosis
Primary: Proportion of Participants Who Are Successfully Down Staged to Resectable Based on Peritoneal Carcinomatosis Index (PCI) and Principal Investigator (PI) Discretion…
Metastatic Melanoma · Stage III Melanoma · Stage IV Melanoma
Primary: Phase 1 Regimen Limiting Toxicity of the Combination of Indoximod and Ipilimumab — 0; 1 Participants
Hypersensitivity · Food Allergy · Hypersensitivity, Food
Primary: The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC) — 19; 27; 3 Participants — p=0.16
Recurrent Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Untreated Adult Acute Myeloid Leukemia
Primary: Biochemical Response — 0 Participants
Chronic Graft Versus Host Disease
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 3; 3; 10; 0 participants
Intestinal Failure · CRBSI - Catheter Related Bloodstream Infection
Primary: Rate of Catheter Related Bloodstream Infections — 8.2; 3.0 infections per 1000 catheter days
NASH - Nonalcoholic Steatohepatitis
Primary: Safety and Tolerability of Treatment — 12; 13; 13; 18 Participants
Alcohol; Use, Problem · Stress · Binge Eating
Primary: Alcohol Consumption (AUDIT-C Score) — 2.933; 2.574; 3.167; 2.619 AUDIT-C score — p=0.4226
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus — 11; 4 Participants
Advanced Solid Tumor
Primary: Incidence of Dose Limiting Toxicities (DLTs) (Phase 1 Part 1A Only) — 0; 0; 0; 1 Participants
Colon Cancer · Colorectal Cancer
Primary: Maximum Tolerated Dose (MTD) of Celebrex in Combination With EPO906 — 9 mg/m2
Malignant Peripheral Nerve Sheath Tumors · Neurofibromatosis 1
Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion
Septic Shock
Primary: Feasibility of Clinical and Protocol Completion — 10; 10 Participants
Moderate-to-Severe Atopic Dermatitis
Primary: Nemolizumab Serum Concentrations — 5950; 2900; 3080; 5150 nanograms per milliliters (ng/mL)